Private equity firm in talks to buy PPD in $4bn deal; reports

By Nick Taylor

- Last updated on GMT

Related tags Ppd Initial public offering David windley

Carlyle Group is in exclusive talks to buy PPD in a deal valuing the CRO at around $4bn (€2.8bn), according to reports.

Bids from private equity firms valuing PPD at up to $4.3bn have been made as part of the strategic review the company confirmed in July​, reports Bloomberg​. PPD was only interested in private equity bids and Carlyle is now said to lead the pack as it seeks to re-enter the clinical services sector.

Carlyle knows the space. It may have been many years ago, but Carlyle owned PRA International for many of its early growth years prior to selling to Genstar and then the IPO [initial public offering]​”, David Windley, equity analyst at Jefferies & Company, said in a note to investors.

A sale price of $35 to $36 a share, close to $4bn in total, “seems achievable​”, Windley said. Before news of the Carlyle bid broke PPD shares were trading at $27 and analyst target prices seen by Outsourcing-Pharma ​range from $36 to $38.

Valuing PPD in light of private equity takeovers of smaller CROs (contract research organisations), such as INC Research, would make $38 reasonable. However, Windley said PPD lacks the top-line growth forecast, cost savings synergies or asset sale opportunities that would justify this price.

It is not hard to imagine the management of a better positioned company believing they should be worth a higher valuation​”, Windley said.

Private benefits

As well as unlocking value for shareholders, the stated goal of the strategic review, going private would free PPD from the reporting requirements of publicly traded companies.

Quintiles has been "the next IPO" in the CRO industry for about four years. Meanwhile, [the CEO] seems to enjoy the communication luxuries of being a private company. In other words, he doesn't have to tell the world what he is up to​”, Windley said.

As a private company Quintiles has entered into “some fairly exotic contract structures and strategic relationships​” that would be disliked by some shareholders, Windley said. PPD could have more scope to enter into these types of deals if it enters private ownership.

Related news

Show more

Related products

show more

How a Clinical MDR Helps with Data Quality

How a Clinical MDR Helps with Data Quality

Formedix | 16-Jan-2023 | Technical / White Paper

This article covers the many ways a clinical metadata repository helps with data quality in the clinical trial process, and how it ultimately helps to...

Optimizing Adherence in DCTs

Optimizing Adherence in DCTs

PPD - Decentralized Clinical Trials | 12-Jan-2023 | Technical / White Paper

Prioritizing greater patient-centricity and creating an opportunity to reach unprecedented patient groups, decentralized and hybrid clinical trials are...

PPD is Supporting Complex EU DCTs

PPD is Supporting Complex EU DCTs

PPD - Decentralized Clinical Trials | 05-Jan-2023 | Technical / White Paper

PPD supports European DCTs and clinical trial sponsors with a holistic and comprehensive approach

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 14-Dec-2022 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Related suppliers

Follow us


View more